Literature DB >> 26950309

Demographic and Clinical Predictors of High Healthcare Use in Patients with Inflammatory Bowel Disease.

Benjamin Click1, Claudia Ramos Rivers, Ioannis E Koutroubakis, Dmitriy Babichenko, Alyce M Anderson, Jana G Hashash, Michael A Dunn, Marc Schwartz, Jason Swoger, Leonard Baidoo, Arthur Barrie, Miguel Regueiro, David G Binion.   

Abstract

BACKGROUND: Inflammatory bowel disease (IBD) is a heterogeneous chronic inflammatory condition requiring significant healthcare expenditure. Subgroups of individuals contribute disproportionately to spending. We aimed to determine demographic and clinical factors predictive of high healthcare expenditures for IBD patients followed over a multiyear period.
METHODS: This was a registry analysis using a prospective observational, consented, natural history registry from a tertiary IBD center and associated medical charges, not including pharmacy expenses. The 100 patients with the highest medical charges (top 5%) were compared with the median 300 patients. Logistic regression determined demographic and clinical factors associated with high charge patients.
RESULTS: IBD patients in the high charge group had significantly more unemployment (P < 0.0001), were of black race (P = 0.013), comorbid psychiatric illness (P = 0.002), hypertension (P = 0.01), diabetes (P = 0.004), opiate use (P < 0.0001), perianal involvement (P = 0.002), penetrating disease (P < 0.0001), and extensive colitis (P = 0.01). In multivariate analysis, unemployment (Crohn's disease [CD]: odds ratio [OR], 3.04; 95% confidence interval [CI], 1.32-7.02; ulcerative colitis [UC]: OR, 2.68; 95% CI, 1.20-5.99), psychiatric illness (UC: OR, 2.08; 95% CI, 1.03-4.19), opiates (CD: OR, 5.61; 95% CI, 2.67-11.82; UC: OR, 5.14; 95% CI, 2.52-10.48), prior surgery (CD: OR, 3.29; 95% CI, 1.59-6.82; UC: OR, 2.72; 95% CI, 1.39-5.32), penetrating CD (OR, 3.29; 95% CI, 1.02-10.62), and corticosteroid requirement (CD: OR, 3.78; 95% CI, 1.86-7.65; UC: OR, 2.98; 95% CI, 1.51-5.90) remained independently associated with high charges.
CONCLUSIONS: High expenditure IBD patients were affected by more severe disease. The high prevalence of depression, anxiety, and chronic pain in these patients suggests the need for focused treatment of these comorbidities ultimately to reduce financial burden.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26950309      PMCID: PMC4868776          DOI: 10.1097/MIB.0000000000000763

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  36 in total

1.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

2.  National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States.

Authors:  Geoffrey C Nguyen; Christopher A Chong; Rachel Y Chong
Journal:  J Crohns Colitis       Date:  2013-09-24       Impact factor: 9.071

3.  Preventing avoidable rehospitalizations by understanding the characteristics of "frequent fliers".

Authors:  Barbara J Mulder; Huey-Ming Tzeng; Nancy D Vecchioni
Journal:  J Nurs Care Qual       Date:  2012 Jan-Mar       Impact factor: 1.597

4.  Generating hypotheses about care needs of high utilizers: lessons from patient interviews.

Authors:  Dawn B Mautner; Hauchie Pang; Jeffrey C Brenner; Judy A Shea; Kennen S Gross; Rosemary Frasso; Carolyn C Cannuscio
Journal:  Popul Health Manag       Date:  2013       Impact factor: 2.459

Review 5.  Psychological interventions for treatment of inflammatory bowel disease.

Authors:  Antje Timmer; Jan C Preiss; Edith Motschall; Gerta Rücker; Günther Jantschek; Gabriele Moser
Journal:  Cochrane Database Syst Rev       Date:  2011-02-16

6.  Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County.

Authors:  Karen Vanessa Winther; Tine Jess; Ebbe Langholz; Pia Munkholm; Vibeke Binder
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

Review 7.  Effectiveness of case management strategies in reducing emergency department visits in frequent user patient populations: a systematic review.

Authors:  Gayathri S Kumar; Robin Klein
Journal:  J Emerg Med       Date:  2012-11-29       Impact factor: 1.484

8.  Psychiatric co-morbidity is associated with increased risk of surgery in Crohn's disease.

Authors:  A N Ananthakrishnan; V S Gainer; R G Perez; T Cai; S-C Cheng; G Savova; P Chen; P Szolovits; Z Xia; P L De Jager; S Y Shaw; S Churchill; E W Karlson; I Kohane; R H Perlis; R M Plenge; S N Murphy; K P Liao
Journal:  Aliment Pharmacol Ther       Date:  2013-01-07       Impact factor: 8.171

9.  Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease.

Authors:  R A Kozarek; D J Patterson; M D Gelfand; V A Botoman; T J Ball; K R Wilske
Journal:  Ann Intern Med       Date:  1989-03-01       Impact factor: 25.391

10.  Cognitive-behavioural therapy has no effect on disease activity but improves quality of life in subgroups of patients with inflammatory bowel disease: a pilot randomised controlled trial.

Authors:  Antonina Mikocka-Walus; Peter Bampton; David Hetzel; Patrick Hughes; Adrian Esterman; Jane M Andrews
Journal:  BMC Gastroenterol       Date:  2015-05-02       Impact factor: 3.067

View more
  28 in total

1.  Reduced Unplanned Care and Disease Activity and Increased Quality of Life After Patient Enrollment in an Inflammatory Bowel Disease Medical Home.

Authors:  Miguel Regueiro; Benjamin Click; Alyce Anderson; William Shrank; Jane Kogan; Sandra McAnallen; Eva Szigethy
Journal:  Clin Gastroenterol Hepatol       Date:  2018-04-12       Impact factor: 11.382

2.  Predicting Costs of Care for Patients With Inflammatory Bowel Diseases.

Authors:  Benjamin Click; David G Binion; Alyce M Anderson
Journal:  Clin Gastroenterol Hepatol       Date:  2016-12-03       Impact factor: 11.382

3.  Modifiable Risk Factors for Hospital Readmission Among Patients with Inflammatory Bowel Disease in a Nationwide Database.

Authors:  Edward L Barnes; Bharati Kochar; Millie D Long; Michael D Kappelman; Christopher F Martin; Joshua R Korzenik; Seth D Crockett
Journal:  Inflamm Bowel Dis       Date:  2017-06       Impact factor: 5.325

Review 4.  The Burden of Cost in Inflammatory Bowel Disease: A Medical Economic Perspective and the Future of Value-Based Care.

Authors:  Jonathan A Beard; Diana L Franco; Benjamin H Click
Journal:  Curr Gastroenterol Rep       Date:  2020-01-30

5.  Factors That Predict High Health Care Utilization and Costs for Patients With Inflammatory Bowel Diseases.

Authors:  Julajak Limsrivilai; Ryan W Stidham; Shail M Govani; Akbar K Waljee; Wen Huang; Peter D R Higgins
Journal:  Clin Gastroenterol Hepatol       Date:  2016-09-17       Impact factor: 11.382

6.  The Burden of Hospital Readmissions among Pediatric Patients with Inflammatory Bowel Disease.

Authors:  Edward L Barnes; Bharati Kochar; Millie D Long; Christopher F Martin; Seth D Crockett; Joshua R Korzenik; Michael D Kappelman
Journal:  J Pediatr       Date:  2017-10-14       Impact factor: 4.406

7.  The Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Inflammatory Bowel Disease.

Authors:  Charles N Bernstein; Lixia Zhang; Lisa M Lix; Lesley A Graff; John R Walker; John D Fisk; Scott B Patten; Carol A Hitchon; James M Bolton; Jitender Sareen; Renée El-Gabalawy; James Marriott; Ruth Ann Marrie
Journal:  Inflamm Bowel Dis       Date:  2018-08-16       Impact factor: 5.325

Review 8.  Depression Treatment Expenditures for Adults in the USA: a Systematic Review.

Authors:  Aaron Samuel Breslow; Nathaniel M Tran; Frederick Q Lu; Jonathan E Alpert; Benjamin Lê Cook
Journal:  Curr Psychiatry Rep       Date:  2019-09-21       Impact factor: 5.285

9.  Development of an Inflammatory Bowel Disease Research Registry Derived from Observational Electronic Health Record Data for Comprehensive Clinical Phenotyping.

Authors:  Alyce J M Anderson; Benjamin Click; Claudia Ramos-Rivers; Dmitriy Babichenko; Ioannis E Koutroubakis; Douglas J Hartman; Jana G Hashash; Marc Schwartz; Jason Swoger; Arthur M Barrie; Michael A Dunn; Miguel Regueiro; David G Binion
Journal:  Dig Dis Sci       Date:  2016-09-12       Impact factor: 3.199

Review 10.  Managing Pain and Psychosocial Care in IBD: a Primer for the Practicing Gastroenterologist.

Authors:  Emily Weaver; Eva Szigethy
Journal:  Curr Gastroenterol Rep       Date:  2020-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.